Literature DB >> 12444323

Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study.

M Grosclaude1, P Bouillot, R Alt, F Leynadier, P Scheinmann, P Rufin, D Basset, R Fadel, C André.   

Abstract

BACKGROUND: Sublingual immunotherapy (SLIT) has been demonstrated to be a viable alternative to injection immunotherapy. Administration of high doses of allergens to ensure efficacy has been shown to be well tolerated. The aim of the present study was the first step to address the issue of fast-induction regimens using various induction SLIT regimens in paediatric and adult patients.
METHODS: Sixty-four patients (age range 5-46 years) with grass pollen rhinoconjunctivitis were enrolled in an 8-month double-blind, placebo-controlled trial of SLIT. Sixty-three patients were randomized to four groups and evaluated at the end of the study. One group received placebo (n = 16) and the other three groups (n = 47) received five grass pollen extracts according to three different induction regimens: regimen 1 starting with 3 IR tablets (n = 15), regimen 2 starting with 10 IR (n = 16) and regimen 3 starting with 30 IR (n = 16). The maintenance phase was made with sublingual-swallow drops at the same concentration of 300 IR/ml for all the patients. Adverse events were recorded on diary cards.
RESULTS: During induction phase, 25/47 patients in the SLIT groups had adverse reactions in comparison to 2/16 patients in the placebo group (p < 0.05). The rate of adverse reactions was 33.3% (11.8-61.6) (95% CI) for regimen 1, 31.3% (11.0-58.7) for regimen 2, 43.8% (19.8-70.1) for regimen 3 and 12.5% (1.6-38.3) for placebo. Fifty-seven reactions were local reactions involving the oral region (54 SLIT, 3 placebo) and 13 were systemic reactions (all in the SLIT groups). 11/13 reactions were mild (gastrointestinal disorders, rhinoconjunctivitis), 1/13 consisted of moderate asthma and 1/13 consisted of severe abdominal pain. No urticaria, angioedema or life-threatening events were observed.
CONCLUSIONS: These preliminary data showed that various induction regimens for SLIT are generally well tolerated and could allow a fast build-up phase of SLIT. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12444323     DOI: 10.1159/000066779

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules.

Authors:  D Passali; R Mösges; G C Passali; F M Passali; G Ayoko; L Bellussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-06       Impact factor: 2.124

Review 2.  [Allergen-specific Immunotherapy for children and adolescents - a review on available products in Austria].

Authors:  Zsolt Szépfalusi; Waltraud Emminger; Franz Eitelberger; Manfred Götz; Andrea Grillenberger; Elisabeth Horak; Isidor Huttegger; Dieter Koller; Helmut Litscher; Rudolf Schmitzberger; Eva-Maria Varga; Josef Riedler
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.

Authors:  Sangmu Jun; Beata Clapp; Dagmara Zlotkowska; Teri Hoyt; Kathryn Holderness; Massimo Maddaloni; David W Pascual
Journal:  Int Immunol       Date:  2011-12-29       Impact factor: 4.823

Review 4.  Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs.

Authors:  Zsolt Szépfalusi; Saskia Gruber; Thomas Eiwegger; Eleonora Dehlink
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

5.  Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy.

Authors:  Joon-Seok Choi; Ha-Ryeong Ryu; Cheol-Hyun Yoon; Ji-Hoon Kim; Jin-Ok Baek; Joo-Young Roh; Jong-Rok Lee
Journal:  Ann Dermatol       Date:  2015-02-03       Impact factor: 1.444

Review 6.  Sublingual immunotherapy for allergic rhinitis.

Authors:  Suzana Radulovic; Moises A Calderon; Duncan Wilson; Stephen Durham
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

7.  Sublingual allergen immunotherapy for respiratory allergy: a systematic review.

Authors:  Carlos Blanco; Raphaelle Bazire; Laura Argiz; Jenaro Hernández-Peña
Journal:  Drugs Context       Date:  2018-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.